yeah IMHO the market fluctuating by a few percent is normal movement - it’s just not understanding this deal as it didn’t understand Paxalisib in the beginning and this is another new instigational drug moving one way or the other by a few percent doesnt say much if anything at all about the drug or the deal or the company - it says everything about the holder and what we all know
imho you back management with the expertise to make these decisions as without the experience most don’t know if this is good or not... it’s great!
look at Paxalisib we had it and SP trended down for quiet a while even when collaboration after collaboration opened up As well as restructures, rebrands etc etc - James and team have not been working hard for a couple years - the fruits of 5 years hard work started coalescing into data and SP 1.5 years ago and since then ‘eventually’ the SP had to follow up - now it’s up 400% in a year once more data and deals and independent third parties informed the market the choices were good.
the market seems to think the only metric is the SP yet Paxalisib was the exact same compound last year as it is today - yet the price is now x4 look to the macro trend in charts - after fundamentals
the company has the credibility and now the track record of a game changing selection in Paxalisib - James clearly stated the reason for this EVT801 acquisition at this time is because it is just as exciting... it’s the first as exciting as Paxalisib compound we have come across.
it doesn’t matter what happens in a day to day let alone a week - the view should be in terms of months and years and overall trend as ever it has been.
Paxalisib is in 7 concurrent trials all adding value after 400 million in deals last month - by those who know what they are looking at, we have a huge runway in bank, we have pax in a phase 3 pivotal study, and now the next opportunity is locked and loaded and is as exciting as Paxalisib, and Cantrixil is licences out to a really credible partner.
I’m happy for the market to drive SP down I can see the overall trend is following the good choices made so far.
great to see James walking us through the drug and the rationale - if you are an investor you’ll love this.
